BridgeBio to Participate in BIO USA... Corporate Presentation Also Scheduled

Bridge Biotherapeutics announced on the 8th that it will dispatch a business trip team, including CEO Lee Jung-kyu, to the 2024 BIO International Convention (BIO USA) held in San Diego, California, USA, from the 3rd to the 6th of next month (local time) to conduct follow-up business development discussions for global technology transfer.

Lee Jung-kyu, CEO of Bridge Biotherapeutics

At this BIO USA, Bridge Biotherapeutics plans to share key progress and clinical data related to BBT-877, a new drug candidate under development for pulmonary fibrosis. Following the JP Morgan Healthcare Conference (JPMHC) held last January, the company aims to continue meetings with global pharmaceutical companies through this follow-up schedule about five months later. In particular, as patient enrollment for the multinational Phase 2 clinical trial of BBT-877 has progressed to over approximately 75% of the target, it is expected that discussions on the drug’s efficacy and safety will advance further.

The company also plans to present this information directly on the BIO USA stage. Selected as a presenting company this year, Pavel Prinsev, Director of Business Development, will share the development status and key milestones of major clinical projects, including BBT-877, BBT-207, a non-small cell lung cancer treatment candidate, and BBT-301, an idiopathic pulmonary fibrosis treatment candidate, on the afternoon of the 3rd.

Lee Jung-kyu, CEO of Bridge Biotherapeutics, said, "As the competitive environment becomes increasingly fierce, we are continuously securing internal data that gives us confidence in technology transfer negotiations as clinical progress continues." He added, "With dozens of one-on-one partnering meetings planned at this year’s BIO USA, we will do our best to showcase prompt business development achievements."

This content was produced with the assistance of AI translation services.